Skip to main content

Take a Tour: Parexel's Early Phase Clinical Unit (EPCU) in California

Our fully integrated network of Parexel Early Phase Clinical Units (EPCUs) comprise four clinical pharmacology facilities in Europe (Berlin), United Kingdom (London) and the USA (Maryland and California) offering our clients a wide variety of specialized services and niche capabilities. We support a full scope of services from first-in-human (FiH) through proof-of-concept (PoC) studies in both normal healthy volunteers and special or patient populations. This includes single and multiple dose escalation, pharmacokinetic (PK) and pharmacodynamic (PD), bioequivalence/bioavailability (BE/BA), food-effect, drug-drug interaction (DDI), thorough QTc (TQT), and ethnobridging studies.